Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven ...

Healx is an AI-enabled, clinical-stage biotech company and was named Life Science AI champion at September’s Business Weekly ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €112.00. David Risinger has given his Buy rating due to a ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand ...

Advt The open offer has been triggered by Sanofi and CD&R entering into exclusive negotiations for the potential sale and purchase of a 50 per cent controlling stake in Opella, Sanofi's consumer ...

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing iconic ...

Sanofi said on Monday (Oct 21) it had entered exclusive talks for the sale of a 50 per cent controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice ...

According to Sanofi, the sale of a controlling 50 percent stake in Opella to Clayton Dubilier & Rice (CD&R) has valued the maker of France's leading painkiller, Doliprane, at €16 billion. " ...